Cart
sales@molnova.com
Palbociclib hydrochloride
CAS No. 827022-32-2
Palbociclib hydrochloride ( PD-0332991 hydrochloride;PD0332991 hydrochloride;PD 0332991 hydrochloride )
Catalog No. M16069 CAS No. 827022-32-2
A potent and selective inhibitor of CDK4/6 with IC50 of 11 nM/16 nM; no inhibition for CDK2A (IC50>5 uM); inhibits MDA-MB453 cells with IC50 of 0.16 uM.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 45 | In Stock |
|
| 10MG | 57 | In Stock |
|
| 50MG | 81 | In Stock |
|
| 100MG | 101 | In Stock |
|
| 200MG | 126 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NamePalbociclib hydrochloride
-
NoteResearch use only, not for human use.
-
Brief DescriptionA potent and selective inhibitor of CDK4/6 with IC50 of 11 nM/16 nM; no inhibition for CDK2A (IC50>5 uM); inhibits MDA-MB453 cells with IC50 of 0.16 uM.
-
DescriptionA potent and selective inhibitor of CDK4/6 with IC50 of 11 nM/16 nM; no inhibition for CDK2A (IC50>5 uM); inhibits MDA-MB453 cells with IC50 of 0.16 uM; shows antiproliferative effect against retinoblastoma (Rb)-positive tumor cells in vitro and reduces the phospho-Ser780/Ser795 on the Rb protein; orally bioavailable.Breast Cancer Approved
-
SynonymsPD-0332991 hydrochloride;PD0332991 hydrochloride;PD 0332991 hydrochloride
-
PathwayAngiogenesis
-
TargetCDK
-
RecptorCDK2/CyclinA;CDK2/CyclinE2;CDK4/CyclinD1;CDK4/CyclinD3;CDK6/CyclinD2
-
Research AreaCancer
-
IndicationBreast Cancer
Chemical Information
-
CAS Number827022-32-2
-
Formula Weight483.99
-
Molecular FormulaC24H30ClN7O2
-
Purity>98% (HPLC)
-
SolubilityDMSO: 6 mg/mL (Need ultrasonic or warming)
-
SMILESCl.CC(=O)C1=C(C)C2=CN=C(NC3=NC=C(C=C3)N3CCNCC3)N=C2N(C2CCCC2)C1=O
-
Chemical NamePyrido[2,3-d]pyrimidin-7(8H)-one, 6-acetyl-8-cyclopentyl-5-methyl-2-[[5-(1-piperazinyl)-2-pyridinyl]amino]-, hydrochloride (1:1)
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Toogood PL, et al. J Med Chem. 2005 Apr 7;48(7):2388-406.
2. Fry DW, et al. Mol Cancer Ther. 2004 Nov;3(11):1427-38.
3. Baughn LB, et al. Cancer Res. 2006 Aug 1;66(15):7661-7.
2. Fry DW, et al. Mol Cancer Ther. 2004 Nov;3(11):1427-38.
3. Baughn LB, et al. Cancer Res. 2006 Aug 1;66(15):7661-7.
molnova catalog
